PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target.
PTEN
anti-EGFR
bevacizumab
colorectal cancer
target therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Nov 2019
09 Nov 2019
Historique:
received:
28
09
2019
revised:
31
10
2019
accepted:
06
11
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
14
11
2019
Statut:
epublish
Résumé
Molecular assessment of colorectal cancer (CRC) is receiving growing attention, beyond RAS and BRAF, because of its influence on prognosis and prediction in cancer treatment. PTEN (phosphatase and tensin homologue), a tumor suppressor, regulating cell division and apoptosis, has been explored, and significant evidence suggests a role in cetuximab and panitumumab resistance linked to the epidermal growth factor receptor (EGFR) signal transduction pathway. Factors influencing PTEN activity should be analyzed to develop strategies to maximize the tumor suppressor role and to improve tumor response to cancer treatment. Therefore, an in-depth knowledge of the PI3K-Akt pathway-one of the major cancer survival pathways-and the role of PTEN-a major brake of this pathway-is essential in the era of precision medicine. The purpose of this literature review is to summarize the role of PTEN as a predictive factor and possible therapeutic target in CRC, focusing on ongoing studies and the possible implications in clinical practice.
Identifiants
pubmed: 31717544
pii: cancers11111765
doi: 10.3390/cancers11111765
pmc: PMC6896095
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Cell. 2009 Mar 3;15(3):167-70
pubmed: 19249675
Cancer Cell Int. 2019 Apr 2;19:80
pubmed: 30983885
Mol Cancer Res. 2013 Feb;11(2):140-8
pubmed: 23239809
Cancer Res. 1998 Nov 15;58(22):5002-8
pubmed: 9823298
Invest New Drugs. 2013 Oct;31(5):1257-64
pubmed: 23504398
Cancer Res. 2008 Mar 15;68(6):1953-61
pubmed: 18339877
Mol Ther Methods Clin Dev. 2017 Nov 21;9:12-22
pubmed: 29255742
Nature. 2010 Jun 24;465(7301):1033-8
pubmed: 20577206
Nat Rev Clin Oncol. 2020 Jan;17(1):11-32
pubmed: 31289352
Science. 1997 Mar 28;275(5308):1943-7
pubmed: 9072974
Clin Cancer Res. 2017 May 1;23(9):2143-2153
pubmed: 28143872
ESMO Open. 2019 Mar 5;4(2):e000464
pubmed: 30962963
J Transl Med. 2011 Jun 25;9:97
pubmed: 21702981
J Clin Invest. 2010 Jun;120(6):2094-108
pubmed: 20458142
Cancer. 2018 Jun 1;124(11):2337-2346
pubmed: 29579325
Br J Cancer. 2005 May 9;92(9):1711-9
pubmed: 15870831
Invest New Drugs. 2019 Jun;37(3):482-489
pubmed: 30302599
Curr Drug Targets. 2014 Jan;15(1):65-79
pubmed: 24387334
Hum Pathol. 2005 Jul;36(7):768-76
pubmed: 16084946
Clin Cancer Res. 2012 Oct 15;18(20):5796-805
pubmed: 22927482
Int J Biol Markers. 2015 Feb 24;30(1):e73-80
pubmed: 24980447
Clin Cancer Res. 2013 Jul 15;19(14):3987-95
pubmed: 23743569
J Clin Oncol. 2009 Dec 10;27(35):5924-30
pubmed: 19884556
World J Gastroenterol. 2003 Mar;9(3):491-4
pubmed: 12632503
J Clin Oncol. 2008 Apr 1;26(10):1603-10
pubmed: 18332469
J Clin Oncol. 2009 Jun 1;27(16):2622-9
pubmed: 19398573
Mol Cell Biol. 2009 Oct;29(19):5377-88
pubmed: 19635806
J Clin Invest. 2010 Aug;120(8):2858-66
pubmed: 20664172
Cancer Sci. 2012 Mar;103(3):528-34
pubmed: 22145922
Oncotarget. 2014 Feb 15;5(3):587-98
pubmed: 24583822
Cell Chem Biol. 2019 Aug 15;26(8):1133-1142.e4
pubmed: 31155509
Adv Exp Med Biol. 2018;1110:55-73
pubmed: 30623366
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
Clin Cancer Res. 2014 Feb 1;20(3):744-53
pubmed: 24218517
Am J Pathol. 1999 Oct;155(4):1253-60
pubmed: 10514407
Cell Rep. 2014 Jan 30;6(2):377-87
pubmed: 24440717
Science. 2009 Sep 4;325(5945):1261-5
pubmed: 19729658
Acta Oncol. 2014 Jul;53(7):852-64
pubmed: 24666267
Oncol Rep. 2009 Oct;22(4):757-64
pubmed: 19724853
Cell. 2007 Jan 12;128(1):157-70
pubmed: 17218262
Nat Med. 2004 Jun;10(6):594-601
pubmed: 15156201
World J Gastroenterol. 2013 Dec 28;19(48):9307-17
pubmed: 24409057
Biosci Rep. 2019 Mar 22;39(3):
pubmed: 30842340
Asian Pac J Cancer Prev. 2012;13(12):6397-401
pubmed: 23464465
J Oncol. 2010;2010:835680
pubmed: 20224655
Science. 2013 Jul 26;341(6144):399-402
pubmed: 23744781
Am J Pathol. 2002 Aug;161(2):439-47
pubmed: 12163369
Curr Cancer Drug Targets. 2008 Feb;8(1):19-26
pubmed: 18288940
Clin Transl Oncol. 2015 Apr;17(4):306-13
pubmed: 25257839
Oncol Lett. 2011 Nov;2(6):1219-1224
pubmed: 22848291
Anticancer Res. 2016 Sep;36(9):4537-43
pubmed: 27630293
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Sci Transl Med. 2010 Oct 13;2(53):53ra75
pubmed: 20944090
J Clin Oncol. 2015 Dec 1;33(34):4023-31
pubmed: 26392102
Lancet Oncol. 2011 Jul;12(7):673-80
pubmed: 21664867
Nat Rev Clin Oncol. 2011 May;8(5):302-6
pubmed: 21468130
Cancer Lett. 2019 Jun 1;451:68-78
pubmed: 30849479
Mol Cell Biol. 2002 Oct;22(20):7004-14
pubmed: 12242281
Front Oncol. 2014 Jan 16;3:326
pubmed: 24475377
EMBO Mol Med. 2009 Sep;1(6-7):315-22
pubmed: 20049735
Cancer Cell. 2004 Aug;6(2):117-27
pubmed: 15324695
Clin Cancer Res. 2013 Jun 15;19(12):3285-96
pubmed: 23633456
Trends Pharmacol Sci. 2011 Mar;32(3):131-40
pubmed: 21236500
Nat Genet. 1997 Apr;15(4):356-62
pubmed: 9090379
Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96
pubmed: 22473468
BMC Gastroenterol. 2008 Nov 26;8:56
pubmed: 19036165
Cancer Res. 2010 Jul 1;70(13):5457-64
pubmed: 20530668
Br J Cancer. 2007 Oct 22;97(8):1139-45
pubmed: 17940504
Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):3080-3087
pubmed: 31002157
Cancer Med. 2013 Jun;2(3):277-85
pubmed: 23930204
J Cell Biol. 2001 Dec 24;155(7):1129-35
pubmed: 11756467
Ann Oncol. 2012 Jul;23(7):1803-8
pubmed: 22112969
Am J Surg. 2008 Jun;195(6):719-25
pubmed: 18440486
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2427-32
pubmed: 18250332
Diagn Pathol. 2016 Jul 08;11(1):61
pubmed: 27392434
Front Mol Neurosci. 2011 Dec 02;4:51
pubmed: 22144946
J Clin Oncol. 2008 Apr 1;26(10):1588-95
pubmed: 18332470
World J Surg Oncol. 2015 May 20;13:186
pubmed: 25986931
J Thorac Oncol. 2011 Apr;6(4):781-5
pubmed: 21289522
J Cell Physiol. 2019 May;234(5):5664-5673
pubmed: 30488557